CN101306183B - Common turmeric extract fat emulsion injection and its preparation method and use - Google Patents
Common turmeric extract fat emulsion injection and its preparation method and use Download PDFInfo
- Publication number
- CN101306183B CN101306183B CN2008101264177A CN200810126417A CN101306183B CN 101306183 B CN101306183 B CN 101306183B CN 2008101264177 A CN2008101264177 A CN 2008101264177A CN 200810126417 A CN200810126417 A CN 200810126417A CN 101306183 B CN101306183 B CN 101306183B
- Authority
- CN
- China
- Prior art keywords
- extract
- injection
- accounts
- fat emulsion
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides Curcuma wenyujin Y.H.Chen et C.Ling extract fat emulsion injection, and a preparation method and a use thereof, in particular to novel Curcuma wenyujin Y.H.Chen et C.Ling extract fat emulsion injection, which relates to fat emulsion injection and a preparation method and a use thereof more specifically. The Curcuma wenyujin Y.H.Chen et C.Ling extract fat emulsion injection comprises an extract with the total content of sesquiterpene more than or equal to 70 percent by weight, soya lecithin, bean oil, glycerin and water for injection which are mixed uniformly. The extract and the soya lecithin are added into the bean oil, and the temperature is increased to change the mixture of the extract, the soya lecithin and the bean oil into oil phase. The oil is added to the aqueous solution containing glycerin, filmed by a rotary evaporator or uniformly mixed by CO2 critical or supercritical method, added with water for injection, and is homogenized under high pressure until dispersed phase stable aqueous dispersion with the average particle diameter less than or equal to one micrometer is got, thus preparing the injection. The drug effect of the pharmaceutical preparation is significantly improved, and the irritability of the Curcuma wenyujin Y.H.Chen et C.Ling extract fat emulsion injection applied in intravenous injection is reduced with the improved stability.
Description
Patent application of the present invention is application number " 02117218.8 ", the applying date " on April 17th, 2002 ", the dividing an application of title " Curcuma wenyujin extract Injection And Preparation Method And Use " patent application
Technical field
The present invention relates to the new injection type of common turmeric extract, more specifically to the fat milk dosage form.The invention still further relates to the preparation method and the purposes of this dosage form.
Prior art
In recent years, the many research worker in the anticancer natural drug research field all are devoted to study the active anticancer of paclitaxel, the various isomers of elemene, Rhizoma Curcumae Longae extract, common turmeric extract etc. and the various dosage forms of these medicines.
Elemene is a kind of sesquiterpenoids that is present in the certain plants, and Latin is called Elemenum, English Elemene by name, and chemical name is 1-methyl isophthalic acid-vinyl-2,4-diisopropenyl cyclohexane extraction, molecular formula C
15H
24Elemene has multiple isomer, beta-elemene in these isomers, and δ-elemene, γ-elemene have been proved active anticancer.Elemene is the chemical compound that can extract from the volatile oil of plant RADIX CURCUMAE (Curcuma Wenyujin Y.H.Chen et C.ling) rhizome (being commonly called as warm Rhizoma Curcumae), or the chemical compound that from the oil of plant Herba Cymbopogonis Citrari (Cymbopoqoncitratus (DC.) Stapt), extracts, for example remove the remaining afterwards mixing grease of citral, citronellol from citronella oil, the chemical compound of extraction is actually the elemene isomer mixture that comprises beta-elemene.
Above-mentioned plant RADIX CURCUMAE and other two kinds of plant Rhizoma Curcumae and Rhizoma Curcumae Longaes that can be used as the natural drug use belong to the zingiberaceous plant monoid, originate in provinces such as Chinese Guangdong, Sichuan, Fujian, Guangxi, Zhejiang.The plant that comprises elemene has kinds more than 50 such as RADIX CURCUMAE, Herba Cymbopogonis Citrari, Rhizoma Acori Calami, Radix Inulae, Radix Ginseng, and wherein Herba Cymbopogonis Citrari is, resource competent plant wide in China's distribution.At present, the Elemene vinyl chemical compound mainly extracts from RADIX CURCUMAE oil and citronella oil.
There are many documents to relate to the herbal medicinal product of the anti-curing cancers of direct employing natural drug preparation, for example the open CN1216256A of Chinese patent discloses the herbal medicinal product of treatment hepatocarcinoma, it comprises contains Herba Hedyotidis Diffusae, Rhizoma Curcumae Longae, the extract of Rhizoma Polygoni Cuspidati and Radix Sophorae Tonkinensis as the Injectable composition (A) of main natural drug and the extract that contains Herba Hedyotidis Diffusae, Rhizoma Paridis, Rhizoma Polygoni Cuspidati, Radix Sophorae Tonkinensis, Radix Gentianae, Radix Et Rhizoma Rhei, Fructus Forsythiae, Radix Paeoniae Rubra, Rhizoma Curcumae Longae and Rhizoma Acori Graminei as the main Orally administered composition (B) of natural drug.
Curcumin preparation is disclosed in the open CN1302559 of Chinese patent; it is by preparing in the blendable organic solvent of water or the curcumin molecular dispersoid in the mixture of water and the blendable organic solvent of water; add protecting colloid aqueous solution, the hydrophobic millimicro decentralized photo that forms mutually of curcumin to this solution then.Final dosage form mainly is aqueous dispersion or dry powder, and particle diameter is less than 10 μ m in the preferred case.
The method of extracting beta-elemene by the secondary fractional distillation from citronella oil is disclosed in CN1200266A.
Disclose the Jiangyu injecta that is used for the treatment of malignant tumor in the open CN1247756A of Chinese patent, wherein the weight ratio of Rhizoma Curcumae Longae and Radix Curcumae is 50-60: 50-40, and this injection is a kind of simple mixture.
The open CN1076613A of Chinese patent relates to elemene emulsion injection and preparation method thereof, and this injection is a kind of emulsion, and mean diameter generally is no more than 15 microns, is no more than 2 microns especially.
The open CN1244389A of Chinese patent relates to elemene injection and preparation method thereof, and this injection is a kind of simple mixtures, is not liposome.
The open CN1110134A of Chinese patent relates to liposome preparation technology and preparation, the elemene liposome injecta of wherein having described the elemene liposome injecta preparation method especially and having obtained by this method, the envelop rate of elemene reaches more than 85%, but does not provide the data of the mean diameter of related lipase plastid.Can judge that from preparation method this liposome has bigger mean diameter.
The open CN1221607A of Chinese patent relates to and utilizes CO
2Critical or supercritical process prepare the technology of liposoluble medicinal liposome and prepared elemene liposome injecta, though the envelop rate of the liposome of elemene is very high, the mean diameter of liposome is equally too big.
More than the disclosed preparation of these documents on bin stability and active anticancer, all exist deficiency.
The various derivants and the elemene metal complex of elemene are also disclosed in some patent documentations in addition.For example, a kind of elemene metal complex and its use as cancer therapy drug are disclosed in CN11531158A.CN1153167A relates to elemene derivatives containing nitrogen and as the purposes of cancer therapy drug.CN1153168A relates to elemene hydroxyls derivs and as the purposes of cancer therapy drug.
Summary of the invention
The purpose of this invention is to provide common turmeric extract fat emulsion injection.
Another object of the present invention provides the preparation method of this injection type.
A further object of the present invention provides the purposes that common turmeric extract fat emulsion injection is used to prepare the drug injection for the treatment of cancer or cerebral infarction, these injection types are used for the purposes of tumor remission pain, and the purposes that is used to suppress and/or treat tumor.
The invention provides the novel form of these medicines.Be prepared into the fat milk dosage form with common turmeric extract respectively as raw material.The mean diameter of these dosage forms is generally less than or equals 1 micron, even is less than or equal to 100 nanometers.
The accompanying drawing summary
Fig. 1 is the transmission electron microscope photo of the 1A preparation of embodiment 1.
Detailed description of the present invention
Known in the prior art field that some isomer of elemene, Rhizoma Curcumae Longae extract, common turmeric extract possess the effect that suppresses tumor, some documents disclose the various dosage forms (or dosage form) of these natural drugs, for example preparations such as liposome, Emulsion, fat milk.But, because the mean diameter of these dosage forms is generally bigger, can cause the intravital various reactions of human or animal after being expelled in the human or animal body, for example zest is big, and haemolysis sometimes takes place.
The inventor is through years of researches work, discovery with sesquiterpene compounds or the extract that contains sesquiterpene that from plant, extracts make mean diameter≤1 micron or≤the various injection types of 100 nanometers, comprising the liposome dosage form, the nanometer liposome dosage form, the pro-liposome dosage form, the long circulating liposomes dosage form, the long-circulating nanoliposome dosage form, nanometer microemulsion type, vein emulsion type, lipid nanometer microsphere dosage form, fat milk dosage form etc., can overcome the problems in the ejection preparation of prior art, these dosage forms especially of the present invention have significantly reduced zest in intravenous injection is used, and their stability is further enhanced.Novel form of the present invention has significantly improved the drug effect of pharmaceutical preparation, but the mechanism of the anticancer of these dosage forms also is not fully aware of at present.The inventor makes following supposition according to a large amount of result of the tests: because preparation of the present invention has little mean diameter and has special surface nature (hydrophile/lipophile balance for example, surface charge etc.), make the medicine (or active component) in these preparations stronger affinity be arranged to cancerous cell, can fully be attached on the cancerous cell, allow active component directly act on cancerous cell, reach the effect that suppresses or kill cancerous cell.In addition, find that the preparation of nano particle size is rapid-action, prevents that from there is certain effect the cancer cell metastasis aspect.
Simultaneously, although preparation of the present invention has little mean diameter, the preparation of the various dosage forms that obtained has high stability simultaneously, and they coagulation problems can not take place in storing for a long time, makes can store the long period and do not reduce stability.
The invention provides common turmeric extract fat emulsion injection, it contains: the extract with total sesquiterpene alkene class content 〉=70wt% that extracts from the RADIX CURCUMAE plant, soybean phospholipid, soybean oil, glycerol and water for injection, this injection is a kind of aqueous dispersion, the mean diameter of decentralized photo≤1 micron, wherein extract accounts for 0.08～0.8wt% of final preparaton total amount, soybean phospholipid accounts for 0.8～2.5wt%, soybean oil accounts for 8～12wt%, glycerol accounts for 1.8～2.8wt%, water for injection adds to 5000ml, and the ultimate density of sesquiterpene active component is 1-10mg/ml in the common turmeric extract fat emulsion injection.
The invention provides the preparation method of common turmeric extract fat emulsion injection, it comprises the steps:
(1), from the RADIX CURCUMAE plant, extracts the extract of total sesquiterpene alkene class content 〉=70wt%;
(2), extract that step (1) is obtained is according in extract and the soybean phospholipid adding soybean oil, heats up into oil phase, and this oil phase is joined in the glycerinated aqueous solution, utilizes Rotary Evaporators film forming or CO
2Critical or supercritical process mix homogeneously, add water for injection, handle through high pressure homogenizing, till the stabilized aqueous dispersion that obtains particle diameter of dispersing phase≤1 micron, thereby make injection, wherein extract accounts for the 0.08wt%～0.8wt% of final preparaton total amount, soybean phospholipid accounts for 0.8wt%～2.5wt%, soybean oil accounts for 8wt%～12wt %, glycerol accounts for 1.8wt%～2.8wt%, water for injection adds to 5000ml, and the ultimate density of sesquiterpene active component is 1-10mg/ml's in the common turmeric extract fat emulsion injection.
The sesquiterpene that extracts from plant (sometimes being called active component here) that can be used for making novel form in the present invention consists essentially of whole sesquiterpene compounds (C15H24), the mixture of sesquiterpene compounds or the sesquiterpene extract that from plant, extracts, extracting product for these requires the purity of sesquiterpene compounds more than 70%, preferably more than 75%, more preferably more than 85%, particularly preferably in more than 90%, even particularly preferably in more than 95%.
It is to be noted, the various raw materials that are used to prepare the preparation of various dosage forms in the present invention can use product such as elemene product (extract), beta-elemene product (extract), Rhizoma Curcumae Longae extract or the common turmeric extract that is purchased, and the extract product of SHULANHUA, Fructus Tonnae Sinensis, Caulis Piperis Kadsurae, Flos Caryophylli, Myrrha, Hemerocallis citrina Baroni Cuculus polioephalus, caraway, Herba thymi vulgaris, parsley, Herba Pogostemonis, Atractylodes lancea (Thunb.) DC., Fructus Cnidii, Flos lupuli (Flos Humuli Lupuli), sandalwood, bergamot, opoponax, Cupressus funebris Endl., Oleum Terebinthinae and Herba Cymbopogonis Citrari, Radix Ginseng etc.If need oneself these extract of preparation in this application, the various volatile oil that are used to prepare these extracts can use and be purchased product, also can use the volatile oil that obtains from plant by common steam distillation or molecularly distilled.
Sesquiterpene comprises elemene (elemene), curcumene (curcumene), zingiberene (zingiberene), bourbonene (bourbonene), humulene (humulene), Acacia farnesiana Willd. ellagic acid (farnesene), cadinene (cadinene), selinene (selinene), maaliene (maaliene), santalene (santalene), patchoulene (patchonlene), caryophyllene (be also referred to as Flos Caryophylli alkene, caryophyllene), gima ethylenic (big myrcene, germacrene), Cubeb oil alkene (cubebene), cedrene (cedrene), longifolene (longifolene), bisabolene (or bisabolene, bisabolene), bergaptene (bergamotene), gurjunene (gurjunene), lignum-vitae alkene (guaiene), ylangene (ylangene), isocaryophyllene (isocaryophyllene), long pinene (longipinene), Rhizoma Acori Calami alkene (calarene), wood sieve alkene (muurolene), acoradiene (acoradiene), sesquiphellandrene (β-sesquiphellandrene) etc.
In principle, all extracts that contain the above sesquiterpene of 60wt% that extract from plant all can be used for preparing novel form of the present invention, and sesquiterpene is the active component of all dosage forms.The extract that contains the above sesquiterpene of 70wt% is ideal, the extract that contains the above sesquiterpene of 75wt% is preferred, the extract that contains the above sesquiterpene of 85wt% is preferred, contain 90wt% above or even the extract that contains the above sesquiterpene of 95wt% be particularly preferred.
The extract that contains elemene that extracts from natural plants contains α-elemene, beta-elemene, δ-elemene, γ-elemene, bourbonene etc. usually.In the present invention as specific embodiment, with RADIX CURCUMAE Curcuma wenyujin Y.H.Chen et C.Ling volatile oil, citronella oil Cymbopoqon citratus (DC.) Stapt submember (citronella oil is removed the remaining afterwards mixing grease of citral, citronellol) is raw material, makes with extra care out elemene through material filling type vacuum rectifying apparatus or molecular distillation instrument.
In addition, each elemene isomer such as α-elemene, beta-elemene, δ-elemene or γ-elemene are as long as purity also can be used in more than 85wt% and makes novel form of the present invention.
At present according to the domestic elemene quality standard (national drug standards WS that issues referring to National Drug Administration in 2000
1-(X-094)-2000Z), (carbowax-20M is an immobile phase with gas chromatography as if separated products (extract), white diatomite carrier 60～80 orders, column temperature is 135～140 ℃, number of theoretical plate calculates by beta-elemene and should be not less than 1000) detect total elemene isomer purity and reach 〉=85% this products known as elemene, reach as if detecting beta-elemene purity 〉=95% product is a beta-elemene, in fact this is inaccurate, because use for example 30 meters long capillary gas chromatograph-mass spectrometer (GC-MS) (chromatographs: Bio-Rad FTS-65A of the higher chromatographic apparatus of sensitivity, HP5890II, chromatographic column: BP-5) detect this 〉=the beta-elemene sample of 95% purity, can find that it still contains at least 6% bourbonene (at the chromatographic chromatogram of muting sensitivity, the peak of beta-elemene becomes a peak with the peak overlapping of bourbonene), the elemene sample is the mixture of multiple sesquiterpene, promptly contain beta-elemene, δ-elemene, γ-elemene, bourbonene, Flos Caryophylli alkene, gima ethylenic etc.
Rhizoma Curcumae Longae Rhizoma Curcuma Longa L. extract is the product that extracts from the volatile oil that curcuma plant obtains.In the present invention as specific embodiment, Rhizoma Curcumae Longae extract refers to the extract that Rhizoma Curcumae Longae volatile oil is made with extra care out through material filling type vacuum rectifying apparatus or molecular distillation instrument, detect through GC-MS, Rhizoma Curcumae Longae extract contains 〉=70wt% usually, preferably 〉=75wt%, more preferably 〉=and 80wt%, preferred especially 〉=85wt%, even more preferably 〉=curcumin of the sesquiterpene of 90wt% such as curcumene, zingiberene etc. and a small amount of (be equivalent to whole sesquiterpene gross weights about 1/25～1/5).
RADIX CURCUMAE Curcuma wenyujin Y.H.Chen et C.Ling extract comprises the product that extracts in the volatile oil that obtains from the RADIX CURCUMAE plant.In this application as specific embodiment, common turmeric extract refers to that RADIX CURCUMAE volatile oil is through smart distilled component of vacuum material filling type rectifier unit or the product made with extra care out through the molecular distillation instrument, detect through GC-MS, product contains 〉=70wt%, preferably 〉=75wt%, more preferably 〉=80wt%, preferred especially 〉=85wt%, even more preferably 〉=sesquiterpene of 90wt% such as various elemene isomer, gima ethylenic, Flos Caryophylli alkene etc. and the curcumin of a small amount of (the about 1/50-1/10 that is equivalent to whole sesquiterpene gross weights).
The explanation of term:
Described in the present invention particle diameter or granularity are meant the particle diameter or the granularity of decentralized photo.
In this application, common turmeric extract refers to that RADIX CURCUMAE volatile oil is through the smart distilled component of vacuum material filling type rectifier unit or the component made from extra care out through the molecular distillation instrument, detect through GC-MS, common turmeric extract contains sesquiterpene and more a spot of curcumin of main amount.
Modify if before dosage form, add " nanometer ", then refer to mean diameter≤150 nanometers of this dosage form, in ideal conditions mean diameter≤100 nanometers.Injection and ejection preparation are used interchangeably.
The liposome dosage form is meant the Lipid Bilayer Structure of being made up of phospholipid and cholesterol etc. that is dispersed or suspended in the water-bearing media in the present invention, and this Lipid Bilayer Structure is similar to membrane structure.
The nanometer liposome dosage form is meant that in the present invention mean diameter is less than or equal to the liposome of 150 nanometers.
The pro-liposome dosage form is meant in the present invention on the prescription basis of liposome and adds excipient again, by the prepared lyophilized powder of vacuum lyophilization (vacuum freeze-drying) method.This lyophilized powder by adding water for injection, through jolting or vibration, made it to revert to the liposome form before clinical practice.
The long circulating liposomes dosage form, briefly, being meant in the present invention increases the prepared liposome of Polyethylene Glycol PHOSPHATIDYL ETHANOLAMINE again on the prescription basis of liposome.The time of playing effectiveness in vivo than common liposome after it is expelled in the body is longer, or eliminates slowly in vivo.
Nanometer microemulsion type refers to mean diameter≤150 nanometers, in the ideal case≤100 the Emulsion of nanometer.
The vein emulsion type refers to the injection breast of mean diameter≤1 micron in the present invention.
Lipid nanometer microsphere dosage form is meant the fat milk of mean diameter≤150 nanometers in the present invention.
The fat milk dosage form requires its mean diameter≤1 micron in the present invention; In the China national pharmacopeia, also stipulate mean diameter≤1 micron in addition.
Nm is meant nanometer, and μ is meant micron.Purity is meant percent purity by weight in this application, except as otherwise noted.
Employed in this application raw material is a common turmeric extract, and its total sesquiterpene alkene class content 〉=70wt% it is desirable to 75wt%, and is preferred 〉=80wt%, more preferably 〉=and 85wt%, preferred 〉=90wt%, more preferred 〉=95wt% especially.This extract contains≤curcumin of 25wt%, contain ideally≤curcumin of 15wt%, and preferably contain≤curcumin of 10wt%, more preferably contain≤curcumin of 5wt%.
Use 30 meters long capillary gas chromatograph-mass spectrometer (GC-MS) Detection and Extraction things described here, contain 〉=extract of 70wt% sesquiterpene just can be used among the present invention.Employed common turmeric extract can be bought with extract (various isomer mixture) or pure isomer (requiring purity to be higher than 85wt%) product form by commercial sources and obtain among the application, also can be as required oneself preparation, for the preparation method of common turmeric extract referring to preparation example.
Employed common turmeric extract raw material, reagent have no particular limits among the application, as long as this extract is to extract from the natural plants RADIX CURCUMAE and total sesquiterpene alkene class purity 〉=70wt% just can use in the present invention, better is, this purity 〉=75wt%, better 〉=80wt%, preferably 〉=85wt%, preferred 〉=90wt% especially.
Except as otherwise noted, otherwise other composition of Shi Yonging requires to meet national medicinal standard as cholesterol, soybean phospholipid, lecithin, glycerol, linoleic acid, Polyethylene Glycol PHOSPHATIDYL ETHANOLAMINE, aliphatic amine, Semen sojae atricolor wet goods in the present invention, solvent also should meet national medicinal standard, and these are mainly for the consideration of healthy aspect; Similarly, modify with " making with extra care " for some raw materials, show that this raw material must meet national medicinal standard, for example refining soybean phospholipid is the available product of injection, and refined soybean oil is the available product of injection.
Except as otherwise noted, otherwise employed in this application gas chromatograph is: Bio-RadFTS-65A, and HP5890II, chromatographic column is: BP-5.
Various dosage form of the present invention can be used for the treatment of purpose with intravenous injection, topical mode.
The preferred embodiments of the invention
In following embodiments, mainly use extract " elemene ", extract " beta-elemene ", Rhizoma Curcumae Longae extract, common turmeric extract, can also use the extract of SHULANHUA, Fructus Tonnae Sinensis, Caulis Piperis Kadsurae, Flos Caryophylli, Myrrha, Hemerocallis citrina Baroni Cuculus polioephalus, caraway, Herba thymi vulgaris, parsley, Herba Pogostemonis, Atractylodes lancea (Thunb.) DC., Fructus Cnidii, Flos lupuli (Flos Humuli Lupuli), sandalwood, bergamot, opoponax, Cupressus funebris Endl., Oleum Terebinthinae and Herba Cymbopogonis Citrari, Radix Ginseng etc. as raw material.Obviously, higher (product for example 〉=85wt%) can both be as raw material, and utilizes synthetic various sesquiterpenes of chemical method and derivant thereof can both be used for the present invention for the purity of wherein a certain sesquiterpene isomer.
The invention provides the preparation method of liposome or nanometer liposome, it comprises: with extract and soybean phospholipid, cholesterol with weight ratio 0.5-1.5: 2.5-4.0: 1.0-2.0, preferred 0.8-1.2: 2.8-3.6: 1.2-1.8, more preferably 0.9-1.1: 3.0-3.4: 1.4-1.6 mixed in preferred especially 1: 3.2: 1.5; Add solvent (as ether or acetone or chloroform), addition is enough to make mixture fully to dissolve, insert and remove the solvent film forming on the Rotary Evaporators, add the water for injection (calculating this surplus) of surplus, insert then in the conventional ultrasonic cell disruptor and carry out ultrasonic Treatment according to the ultimate density that will prepare; Sampling utilizes the microscope of band scale, the Coulter instrument, ultramicroscope is checked mean diameter, at the mean diameter that reaches regulation for example≤1 micron (liposome), or≤100 nanometers (nanometer liposome) after, regulate PH, making pH value is 4.5～6.5, through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃ of vapor stream sterilizations, the ultimate density (weight of sesquiterpene active component (mg)/total volumes of formulation (ml)) of utilizing chromatograph (gas phase or liquid phase) to record active component is 1～10mg/ml, be preferably 2～7.5mg/ml, be more typically 5～7.5mg/ml.
The envelop rate of nanometer liposome detects: detect with sieve method, promptly, utilize the SephadexG25 tomographic system, the extract nano-liposome preparation is divided into two stream parts, be extract nano-liposome stream part and free extract flow part, detect the extractive content that contains in two stream parts through gas chromatograph.The extractive content ÷ of envelop rate computing formula=extract nano-liposome stream part (extractive content+free extractive content of extract nano-liposome stream part).Whether microscope or transmission electron microscope checking are liposome.
The invention provides the preparation method of pro-liposome: with extract and refining soybean phospholipid, cholesterol is with weight ratio 0.5-1.5: 2.5-4.0: 1.0-2.0, preferred 0.8-1.2: 2.8-3.6: 1.2-1.8, more preferably 0.9-1.1: 3.0-3.4: 1.4-1.6, mixed in preferred especially 1: 3.2: 1.5, add solvent (as ether or acetone or chloroform), addition is enough to fully dissolve this mixture, insert and remove the solvent film forming on the Rotary Evaporators, add the water for injection (calculating this surplus) of surplus according to the ultimate density that will prepare, insert ultrasonic cell disruptor then and carry out supersound process, sampling utilizes the microscope or the Coulter instrument of band scale to check mean diameter, behind mean diameter≤1 micron, regulate PH, making pH value is 4.5～6.5, through 0.8 μ filtering with microporous membrane and bottling then, the excipient (for example lactose or average molecular weight Mw are the low molecular dextran of about 4000-40000) that adds the 1-2wt% that accounts for total amount of formulation, 100 ℃ of vapor stream sterilizations, lyophilization under the aseptic condition, embedding.Adding injection water before using is 1～10mg/ml to reach final activity component concentration (weight of sesquiterpene active component (mg)/volumes of formulation (ml)), is preferably 2～8mg/ml, and more preferably 2～7.5mg/ml is more typically 5～7.5mg/ml.
The detection of envelop rate: use the sieve method detection method, that is: according to the final formulation concentrations (mg/ml) that will prepare, the water jolting of a certain amount of extract proliposome preparation being added the surplus volume earlier is even, become liposome this moment again, utilize Sephadex G25 tomographic system to be divided into two stream parts, be extract liposome stream part and free extract flow part, detect the extract amount that contains in two stream parts through gas chromatograph.The extractive content ÷ of envelop rate computing formula=extract liposome stream part (extractive content+free extract amount of extract liposome stream part).Whether microscope or transmission electron microscope confirm is pro-liposome.
The invention provides the preparation method of long circulation extract nano-liposome, this method comprises: with extract and refining soybean phospholipid, Polyethylene Glycol (2000) PHOSPHATIDYL ETHANOLAMINE, cholesterol is with weight ratio 0.5-1.5: 1.5-3.5: 0.3-1.2: 0.8-2.0, preferably with weight ratio 0.8-1.2: 1.8-3.0: 0.4-1.0: 1.2-1.8, more preferably with weight ratio 0.9-1.1: 2.4-2.8: 0.6-1.0: 1.2-1.6, especially preferably with weight ratio 1: 2.6-2.7: 0.7-0.9: 1.3-1.5 mixes, add solvent (as ether or acetone or chloroform), addition is enough to fully dissolve this mixture, insert and remove the solvent film forming on the Rotary Evaporators, add the water for injection (calculating this surplus) of surplus according to the ultimate density that will prepare, insert conventional ultrasonic cell disruptor then and carry out ultrasonic Treatment, sampling utilizes the microscope of band scale, Coulter instrument or ultramicroscope are checked mean diameter, after reaching the mean diameter of regulation (for example≤100 nanometer), regulate PH, making pH value is 4.5～6.5, through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃ of vapor stream sterilizations, the ultimate density (weight of sesquiterpene active component (mg)/total volumes of formulation (ml)) that (gas phase or liquid phase) chromatography records active component is 1～10mg/ml, be preferably 2～7.5mg/ml, more preferably 2～8mg/ml is more typically 5～7.5mg/ml.For Polyethylene Glycol (2000) PHOSPHATIDYL ETHANOLAMINE, wherein " 2000 " refer to the mean molecule quantity (dalton) of Polyethylene Glycol segment.
The detection of the envelop rate of this injection is identical with the envelop rate detection method of the lipidosome injection of front.
The invention provides the preparation method of electronegative and positively charged extract nano microemulsion:
Preparation method 1: the preparation of electronegative nanometer microemulsion
With extract and refining soybean phospholipid, cholesterol is with weight ratio 0.5-1.5: 2.5-4.0: 1.0-2.0, preferred 0.8-1.2: 2.8-3.6: 1.2-1.8, more preferably 0.9-1.1: 3.0-3.4: 1.4-1.6, mixed in preferred especially 1: 3.2: 1.5, add solvent (as ether or acetone or chloroform), addition is enough to fully dissolve this mixture, insert and remove the solvent film forming on the Rotary Evaporators, add the water for injection (calculating this surplus) of surplus according to the ultimate density that will prepare, insert conventional ultrasonic cell disruptor then and carry out ultrasonic Treatment, sampling utilizes the microscope of band scale, Coulter instrument or ultramicroscope are checked mean diameter, after reaching the mean diameter of regulation (for example≤100 nanometer), regulate PH, making pH value is 4.5～6.5, through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃ of vapor stream sterilizations, the ultimate density of active component (weight of sesquiterpene active component (mg)/total volumes of formulation (ml)) is 1～10mg/ml, be preferably 2～7.5mg/ml, be more typically 5～7.5mg/ml.Microscope, transmission electron microscope detect, and confirm whether be the nanometer microemulsion.
Preparation method 2: the preparation of positively charged nanometer microemulsion
With extract, refined lecithin, C14-C22 straight or branched aliphatic amine, cholesterol is with weight ratio 0.5-1.5: 2.5-3.5: 0.2-0.6: 1.0-2.0, preferred 0.8-1.2: 2.5-3.0: 0.3-0.5: 1.2-1.8, more preferably 0.9-1.1: 2.7-2.9: 0.3-0.5: 1.4-1.6, preferred especially 1: 2.8: 0.4: 1.5 mixed, add solvent (as ether or acetone or chloroform), addition is enough to fully dissolve this mixture, insert and remove the solvent film forming on the Rotary Evaporators, add the water for injection (calculating this surplus) of surplus then according to the densitometer that will prepare, insert conventional ultrasonic cell disruptor then and carry out supersound process, sampling utilizes the microscope of band scale, Coulter instrument or ultramicroscope are checked mean diameter, after reaching the mean diameter of regulation (for example≤100 nanometer), regulate PH, making pH value is 7.5～9.0, through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃ of vapor stream sterilizations, the ultimate density of sesquiterpene active component is 1～10mg/ml, be preferably 2～7.5mg/ml, be more typically 5～7.5mg/ml.Microscope, transmission electron microscope detect, and confirm whether be the nanometer microemulsion.
The present invention also provides the preparation method of extract lipid nanospheres, and this method comprises: get extract and add in the soybean oil with soybean phospholipid, heat up and be controlled to oil phase (remaining oil phase), this oil phase is joined in the glycerinated aqueous solution.Its concrete part by weight is: extract accounts for 0.08～0.8wt% of final preparaton total amount, soybean phospholipid 0.8～2.5wt%, and soybean oil 8-12wt%, glycerol 1.8-2.8wt%, water for injection adds to 5000ml; Preferred part by weight is: extract accounts for the 0.1wt%～0.5wt% of final preparaton total amount, soybean phospholipid 1.2wt%～2.0wt%, and soybean oil 10wt%, glycerol 2.25～2.5wt%, water for injection adds to 5000ml.High-speed stirred then, regulating PH is 4.5～6.5, passing through common high pressure homogenizer (for example M110-E/H type (Japanese MIZUHO produces)) again handles, carry out foregoing ultrasonic Treatment then, sampling utilizes microscope, Coulter instrument or the ultramicroscope of band scale to check mean diameter, the mean diameter of its lipid ball reach setting for example≤100nm after, again through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃～120 ℃ sterilizations.The ultimate density that (gas phase or liquid phase) chromatography records the sesquiterpene active component is 1～10mg/ml, is preferably 2～7.5mg/ml, is more typically 2～5mg/ml, and better is 2.0～3.0mg/ml.Can in this final preparation, add an amount of cholesterol, linoleic acid etc. as required.
The invention provides the preparation method of extract intravenous injection breast, this method comprises: with extract, refining soybean phospholipid, cholesterol is with weight ratio 0.5-1.5: 2.5-4.0: 1.0-2.0, preferred 0.8-1.2: 2.8-3.6: 1.2-1.8, more preferably 0.9-1.1: 3.0-3.4: 1.4-1.6, preferred especially 1: 3.2: 1.5, mix with the water for injection (calculating this surplus) of surplus according to the ultimate density that will prepare, high pressure homogenizer (for example M110-E/H type (Japanese MIZUHO produces)) emulsifying with routine, sampling utilizes the microscope or the Coulter instrument of band scale to check mean diameter, the mean diameter that reaches regulation for example≤1 micron after, regulate PH, making pH value is 4.5～6.5, through 1.2 μ filtering with microporous membranes and bottling then, through 100 ℃～120 ℃ sterilizations, obtain extract vein breast, the ultimate density that (gas phase or liquid phase) chromatography records the sesquiterpene active component is 1～10mg/ml, be preferably 2～7.5mg/ml, be more typically 5～7.5mg/ml.
The invention provides the preparation method of extract fat emulsion, this method comprises: get extract and soybean phospholipid and add in the soybean oil, heat up and be controlled to oil phase (remaining oil phase), this oil phase is joined in the glycerinated aqueous solution.Its concrete weight ratio is: extract accounts for 0.08～0.8wt% of final preparaton total amount, soybean phospholipid 0.8～2.5wt%, and soybean oil 8-12wt%, glycerol 1.8-2.8wt%, water for injection adds to 5000ml; Preferred part by weight is: extract accounts for the 0.1wt%～0.5wt% of final preparaton total amount, soybean phospholipid 1.2wt%～2.0wt%, and soybean oil 10wt%, glycerol 2.25～2.5wt%, water for injection adds to 5000ml.High-speed stirred then, regulating PH is 4.5～6.5, passes through common high pressure homogenizer (for example M110-E/H type (Japanese MIZUHO produces)) again and handles, and makes its particle diameter less than 1 μ, again through 1.2 μ filtering with microporous membranes with bottle 100 ℃～120 ℃ sterilizations then.The ultimate density of sesquiterpene active component is 1～10mg/ml, is preferably 2～7.5mg/ml, the better 2.0～3.0mg/ml of being or be 5～7.5mg/ml.Can in this final preparation, add an amount of cholesterol, linoleic acid etc. as required.
As required, preparation of the present invention can with different size for example the microporous filter membrane of 1.2 μ, 1.0 μ, 0.9 μ, 0.8 μ, 0.7 μ, 0.6 μ, 0.5 μ etc. filter, can intercept mean diameter≤0.8 μ ,≤0.7 μ ,≤0.6 μ ,≤0.5 μ ,≤0.45 μ ,≤0.4 μ ,≤decentralized photo of 0.3 μ etc.
Below preparation example and embodiment be used to illustrate the present invention, but should not think and limit the scope of the invention.Protection scope of the present invention is defined by claim.
Preparation example: the preparation of common turmeric extract
Preparation method A: with RADIX CURCUMAE volatile oil is raw material, refining through the Guangzhou Han Wei MD-S80 of mechanical ﹠ electrical corporation type molecular distillation instrument, its process conditions: 35～45 ℃ of vapo(u)rizing temperatures, distillation pressure 70～90Pa, 300～320 rev/mins of knifing speed, 20～25 ℃ of cryosurface temperature, 20～25 ℃ of system temperatures, 15～30 milliliters/hour of material flows are only collected and are heated up in a steamer excess, will heat up in a steamer excess and proceed molecular distillation.Vapo(u)rizing temperature is 45～60 ℃, distillation pressure 30～70Pa, 300～320 rev/mins of knifing speed, 20～25 ℃ of cryosurface temperature, 20～25 ℃ of system's insulations, 15～30 milliliters/hour of material flows, collect distillation respectively and heat up in a steamer excess, will heat up in a steamer excess and carry out molecular distillation.Vapo(u)rizing temperature is 30～70 ℃, distillation pressure 10～50Pa, 300～320 rev/mins of knifing speed, 20～25 ℃ of cryosurface temperature, 20～25 ℃ of system's insulations, 15～30 milliliters/hour of material flows, collect distillation, bleed off and heat up in a steamer excess, the secondary distillation that obtains is mixed, continue distillation, until till the gas chromatograph detection reaches total sesquiterpene alkene content 〉=75wt%, (utilize 30 meters long capillary gas chromatograph-mass spectrometer (GC-MS) gas chromatograpies to detect, chromatograph: Bio-Rad FTS-65A, HP5890II, chromatographic column: BP-5).This extract detects through above-mentioned gas chromatograph, also contains about 1/25 the curcumin that is equivalent to whole sesquiterpene gross weights.Formulate for the detection finger printing with gas chromatography.This products known as common turmeric extract A.
Preparation method B. is RADIX CURCUMAE volatile oil, through the rectification of material filling type vacuum rectifying apparatus,
The material filling type vacuum rectifying apparatus is made of still, stuffing rectification column, return channel, the vacuum pump of dress RADIX CURCUMAE volatile oil; manufacture and design by new packing technology development center of Shanghai Chemical Research Inst; filler is Dixon filler (a Q net ring filler); vacuum is 1～3mmHg, collects the above fraction of 82 ℃/3mmHg.Through the gas chromatograph analysis is sesquiterpenoid (utilizing 30 meters long capillary gas chromatograph-mass spectrometer (GC-MS) gas chromatograpies to detect), total sesquiterpene alkene content 〉=75wt%.Extract detects through above-mentioned gas chromatograph, also contains about 1/25 the curcumin that is equivalent to whole sesquiterpene gross weights.Formulate for the detection finger printing with gas chromatography.This products known as common turmeric extract B.
In addition, the CO that learns from else's experience
2Supercritical extraction is crossed the RADIX CURCUMAE medicinal residues of volatile oil, added the methanol reflux 3 hours, obtain brown solution, remove methanol with Rotary Evaporators, obtain brown dope, should be prepared chromatograph with silica gel by brown thickness paste,, obtain the curcumin product of purity 〉=90wt% with the chloroform eluting.Above-mentioned product A and product B are mixed with 50: 50 weight ratios, formed mixture is mixed in the ratio of 20: 1 (weight) with this curcumin product and obtain another kind of mixture, be called extract C.
Embodiment 1: the preparation of the nano-lipid body injection of common turmeric extract
Program 1A: with the product A and the refining soybean phospholipid of preparation example, cholesterol mixes with weight ratio at 1: 3.2: 1.5, add ether, addition is enough to fully dissolve this mixture, insert and remove the ether film forming on the Rotary Evaporators, add the water for injection (is that 5mg/ml calculates this surplus according to the ultimate density that will prepare) of surplus, insert ultrasonic cell disruptor (model JCS-204) supersound process that Jining, Shandong ultrasonic electronic instrument plant produces then, sampling utilizes the microscope of band scale, Coulter instrument or ultramicroscope are checked mean diameter, after mean diameter≤100 nanometers, regulate PH with 1M biphosphate sodium water solution, making pH value is 4.5～6.5, (new Asia, Shanghai purifies device factory and produces through 0.8 μ microporous filter membrane, specification 0.8 μ) filters and bottling then, 100 ℃ of vapor stream sterilizations, the injection product that is obtained is called for short 1A.Sampling is 5 ± 0.10mg/ml with the ultimate density that gas chromatography (utilizing 30 meters long capillary gas chromatograph-mass spectrometer (GC-MS) gas chromatograpies) records active component (weight (mg) of total sesquiterpene alkene active component/volumes of formulation (ml)).
Detect envelop rate with sieve method, promptly, utilize Sephadex G25 tomographic system that the extract nano-liposome preparation is divided into two stream parts, promptly extract nano-liposome stream part and free extract flow part are detected the extractive content that contains in two stream parts through gas chromatograph.Envelop rate surpasses 85%.The extractive content ÷ of envelop rate computing formula=extract nano-liposome stream part [extractive content+free extract amount of extract nano-liposome stream part].Microscope, transmission electron microscope detect, and confirmation is a nanometer liposome, provides the transmission electron microscope photo (scale 50nm) of this injection in accompanying drawing 1.
Program 1B: repeat above-mentioned 1A program, just replace the product A of preparation example with the product B of preparation example.Microscope, transmission electron microscope detect, and confirm that preparation is a nanometer liposome.The concentration of total sesquiterpene alkene class is about 5 ± 0.10mg/ml in the preparation.Envelop rate is higher than 85%.This injection is called for short 1B.
Embodiment 2: the preparation of the pro-liposome of common turmeric extract
2A: according to the 1A program of embodiment 1 in identical method and proportioning raw materials, repeat the 1A program of embodiment 1, just require particle diameter≤1 micron of decentralized photo after the ultrasonic Treatment and after filtering and before bottling, the lactose that adds the 1-2% that accounts for total weight of formulation, utilize 100 ℃ of vapor stream sterilizations then, lyophilization under the aseptic condition, embedding (packing).Detecting the confirmation preparation with the Coulter instrument is pro-liposome.This injection product is called for short 2A.Envelop rate is higher than 85%.Said preparation added injection water before injection is used be 5 ± 0.10mg/ml to reach final active component (total sesquiterpene alkene class) concentration.
2B: repeating above-mentioned 2A, just replace the product A of preparation example with the B product of preparation example, is about 40000 low molecular dextran replacement lactose with average molecular weight Mw.This injection is called for short 2B.Detecting the confirmation preparation with the Coulter instrument is pro-liposome.Envelop rate is higher than 85%.Said preparation added injection water before injection is used be 5 ± 0.10mg/ml to reach final activity component concentration (weight (mg) of total sesquiterpene alkene class/volumes of formulation (ml)).
Embodiment 3: the preparation of the long-circulating nanoliposome of common turmeric extract
3A: according to the 1A program of embodiment 1 in identical method, repeat the 1A program of embodiment 1, just raw material and their weight proportion are: common turmeric extract A: soybean phospholipid: Polyethylene Glycol (2000) PHOSPHATIDYL ETHANOLAMINE: cholesterol=1: 2.7: 0.8: 1.4.This injection is called for short 3A.Pick test mean diameter≤100nm.The ultimate density of total sesquiterpene alkene class is 5 ± 0.10mg/ml in the preparation.Envelop rate is higher than 85%.
3B: repeat above-mentioned 3A, just replace the product A of preparation example with the product B of preparation example.The injection that is obtained is called for short 3B.Mean diameter≤100nm.The ultimate density of total sesquiterpene alkene class is 5 ± 0.10mg/ml in the preparation.Envelop rate is higher than 85%.
Embodiment 4: the preparation of the nanometer microemulsion of electronegative and positively charged common turmeric extract
4A-1: the preparation of electronegative nanometer microemulsion
Repeat the 1A program of embodiment 1, just do not measure envelop rate.The ultimate density that sampling records total sesquiterpene alkene class is 5 ± 0.10mg/ml.Confirm it is the nanometer microemulsion with the Coulter instrument.This injection product is called for short 4A-1.
4A-2: the preparation of positively charged nanometer microemulsion
Repeat the 1A program of embodiment 1, just raw material and their weight proportion are: extract A: lecithin: n-octadecane base amine: cholesterol=1: 2.8: 0.4: 1.5, do not measure envelop rate.The ultimate density that sampling records total sesquiterpene alkene class is 5 ± 0.10mg/ml.Confirm it is the nanometer microemulsion with the Coulter instrument.This injection is called for short 4A-2.
4B-1: the preparation of electronegative nanometer microemulsion
Repeat above-mentioned 4A-1, just replace the product A of preparation example with the product B of preparation example.The ultimate density that sampling records total sesquiterpene alkene class is 5 ± 0.10mg/ml.Confirm it is the nanometer microemulsion with the Coulter instrument.The injection that is obtained is called for short 4B-1.
4B-2: the preparation of positively charged nanometer microemulsion
Repeat above-mentioned 4A-2, just replace the product A of preparation example with the product B of preparation example.The ultimate density that sampling records total sesquiterpene alkene class is 5 ± 0.10mg/ml.Confirm it is the nanometer microemulsion with the Coulter instrument.The injection that is obtained is called for short 4B-2.
Embodiment 5: the preparation of the lipid nanospheres preparation of common turmeric extract
5A: the extract A of getting preparation example adds in the soybean oil with soybean phospholipid, heats up and is controlled to oil phase (promptly remaining oil phase), and this oil phase is joined in the glycerinated aqueous solution.Its concrete weight ratio is: extract A accounts for 0.2% of total weight of formulation, soybean phospholipid 1.7%, soybean oil 10%, glycerol 2.5%, surplus is a water for injection, high-speed stirred then, regulating PH with 1M biphosphate sodium water solution is 4.5～6.5, handle through M110-E/H type (Japanese MIZUHO produces) high pressure homogenizer again, carry out ultrasonic Treatment according to same procedure among the embodiment 3 then, make the mean diameter≤100nm of its lipid ball, again through 0.8 μ filtering with microporous membrane and bottling then, 100 ℃～120 ℃ sterilizations.The ultimate density that sampling records total sesquiterpene alkene class is 2 ± 0.04mg/ml.The injection that is obtained is called for short 5A.Can in raw material, comprise an amount of cholesterol, linoleic acid etc. as required.
5B: repeat above-mentioned 5A program, just replace the product A of preparation example with the product B of preparation example.Mean diameter≤the 100nm of lipid ball.The ultimate density that chromatography records total sesquiterpene alkene class is 2 ± 0.04mg/ml.The injection that is obtained is called for short 5B.
Embodiment 6: the preparation of the intravenous injection breast of common turmeric extract
6A: the common turmeric extract A of preparation example, refining soybean phospholipid, cholesterol are mixed with the water for injection (is that 5mg/ml calculates this surplus according to required final concentration) of surplus with weight ratio 1: 3.2: 1.5, with M110-E/H type (Japanese MIZUHO produces) high pressure homogenizer emulsifying, till usefulness Coulter instrument checks particle diameter less than 1 μ always.Then, regulate PH with 1M biphosphate sodium water solution, making pH value is 4.5～6.5, through 1.2 μ filtering with microporous membranes and bottling then, through 100 ℃～120 ℃ sterilizations, obtain common turmeric extract vein breast, the ultimate density that sampling records total sesquiterpene alkene class is 5 ± 0.10mg/ml.This injection is called for short 6A.
6B: repeat above 6A, just replace the product A of preparation example with the product B of preparation example.Check particle diameter less than 1 micron with the Coulter instrument.The ultimate density of total sesquiterpene alkene class is 5 ± 0.10mg/ml in the preparation.The injection that is obtained is called for short 6B.
Embodiment 7: the preparation of common turmeric extract fat emulsion
7A: product A and the soybean phospholipid of getting preparation example add in the soybean oil, heat up and are controlled to oil phase, and this oil phase is joined in the glycerinated aqueous solution.Its concrete weight ratio is: extract A accounts for 0.2% of total weight of formulation, soybean phospholipid 1.2%, and soybean oil 10%, glycerol 2.5%, surplus is a water for injection.High-speed stirred then, regulating PH with 1M biphosphate sodium water solution is 4.5～6.5, handles through M110-E/H type (Japanese MIZUHO produces) high pressure homogenizer, until with till Coulter instrument check particle diameter≤1 μ again, again through 1.2 μ filtering with microporous membranes and bottling then, 100 ℃～120 ℃ sterilizations.The ultimate density that records total sesquiterpene alkene class is 2 ± 0.04mg/ml.The injection that is obtained is called for short 7A.Can in raw material, comprise an amount of cholesterol, linoleic acid etc. as required.
7B: repeat above-mentioned 7A, just replace the product A of preparation example with the product B of preparation example.The ultimate density that records total sesquiterpene alkene class in preparation is 2 ± 0.04mg/ml.The injection that is obtained is called for short 7B.
Embodiment 8:CO
2Supercritical methanol technology prepares liposome
8A: the chloroform that will account for the 10wt% of cholesterol weight adds to be made it in the cholesterol to soak into, the extract A adding of soybean phospholipid and preparation example is wherein mixed (extract A: soybean phospholipid: cholesterol=weight ratio 1.2: 3.2: 1.5), the mixture that is obtained is put into CO
2In the extractor of supercritical extraction instrument (Han Wei mechanical ﹠ electrical corporation in Guangzhou produces, model SFE100ml), feed CO
2(pressure 50-80kg), 50 ℃ of system temperatures carry out critical or supercritical dispersion, make the mixture uniform mixing, and slowly decompression discharges CO then
2, allow CO
2Chloroform is taken out of, take out extractor, the water for injection (calculating this surplus) that in extractor, adds surplus according to the ultimate density of injection, stir with agitator, with formed dispersion ultrasonic Treatment, until till decentralized photo particle diameter≤100 nanometers of liposome (being called nanometer liposome).Then liposome is regulated PH with 1M biphosphate sodium water solution, making pH value is 4.5～6.5, filters and bottling then through 0.8 μ microporous filter membrane (new Asia, Shanghai purifies device factory and produces, specification 0.8 μ), 100 ℃ of vapor stream sterilizations, the injection product that is obtained is called for short 8A.Sampling is 5 ± 0.10mg/ml with the ultimate density that gas chromatography records total sesquiterpene alkene class.Envelop rate is higher than 88%.
8B: repeat above-mentioned 8A, just replace the product A of preparation example, make liposome with the product B of preparation example.The ultimate density that records total sesquiterpene alkene class in preparation is 5 ± 0.10mg/ml.The injection that is obtained is called for short 8B.Envelop rate is higher than 88%.
8C: repeat above-mentioned 8A, just replace the product A of preparation example, make liposome with the extract C of preparation example.The ultimate density that records total sesquiterpene alkene class in preparation is 5 ± 0.10mg/ml.The injection that is obtained is called for short 8C.Envelop rate is higher than 88%.
Pharmacodynamics test
The anti-tumor in vivo Evaluation on effect method of pharmaceutical preparation has had description (for example referring to CN1153168A) in above some patent documentation of enumerating.
In the present invention, the preparation of various dosage forms is to human tumor heteroplastic transplantation model QGY hepatocarcinoma, the MKN-45 efficacy in treating gastric carcinoma of subcutaneous vaccination, can be by dosage with 80mg (sesquiterpene)/kg (body weight), 40mg/kg and 20mg/kg, every day, the tail intravenously administrable was 1 time, 10 days therapeutic scheme of successive administration confirms wherein there is not the group in contrast of administration.The relevant regulations " the evaluating drug effect way of antitumor drug " of the National Drug Administration that the calculating of concrete operating process and tumor control rate (tumour inhibiting rate) (referred to before the application's the applying date) according to is at present implemented.
Tumour inhibiting rate %=[(does not have the tumor weight of model of tumor weight-administration of the model of administration)/do not have a tumor weight of the model of administration] * 100%
The tumour inhibiting rate of table 1. human tumor heteroplastic transplantation model QGY hepatocarcinoma
| Injection | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate |
| 1A | 20 | 30.3％ | 40 | 39.2％ | 80 | 45.3％ |
| 1B | 20 | 30.0％ | 40 | 39.1％ | 80 | 45.0％ |
| 2A | 20 | 30.1％ | 40 | 37.5％ | 80 | 44.0％ |
| 2B | 20 | 30.0％ | 40 | 38.5％ | 80 | 43.7％ |
| 3A | 20 | 29.7％ | 40 | 39.7％ | 80 | 44.5％ |
| 3B | 20 | 29.8％ | 40 | 38.7％ | 80 | 44.4％ |
| 4A-1 | 20 | 30.4％ | 40 | 38.5％ | 80 | 46.0％ |
| 4A-2 | 20 | 31.7％ | 40 | 37.9％ | 80 | 46.3％ |
| 4B-1 | 20 | 30.3％ | 40 | 37.4％ | 80 | 45.2％ |
| 4B-2 | 20 | 29.4％ | 40 | 38.7％ | 80 | 44.9％ |
| 5A | 20 | 29.2％ | 40 | 38.6％ | 80 | 44.2％ |
| 5B | 20 | 29.5％ | 40 | 38.7％ | 80 | 44.5％ |
| 6A | 20 | 29.8％ | 40 | 37.8％ | 80 | 43.3％ |
| 6B | 20 | 29.4％ | 40 | 37.9％ | 80 | 43.5％ |
| 7A | 20 | 29.3％ | 40 | 37.4％ | 80 | 44.0％ |
| 7B | 20 | 29.7％ | 40 | 37.3％ | 80 | 43.3％ |
| 8A | 20 | 29.4％ | 40 | 37.4％ | 80 | 44.0％ |
| 8B | 20 | 29.3％ | 40 | 37.3％ | 80 | 43.3％ |
| 8C | 20 | 29.4％ | 40 | 37.7％ | 80 | 44.3％ |
The tumour inhibiting rate of table 2. human tumor heteroplastic transplantation model MKN-45 gastric cancer
| Injection | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate |
| 1A | 20 | 28.9％ | 40 | 39.2％ | 80 | 45.3％ |
| 1B | 20 | 29.1％ | 40 | 39.1％ | 80 | 45.0％ |
| 2A | 20 | 29.2％ | 40 | 37.5％ | 80 | 44.0％ |
| 2B | 20 | 28.4％ | 40 | 38.5％ | 80 | 43.7％ |
| 3A | 20 | 29.1％ | 40 | 39.7％ | 80 | 44.5％ |
| 3B | 20 | 29.0％ | 40 | 38.7％ | 80 | 44.4％ |
| 4A-1 | 20 | 29.4％ | 40 | 38.5％ | 80 | 46.0％ |
| 4A-2 | 20 | 29.5％ | 40 | 37.9％ | 80 | 46.3％ |
| 4B-1 | 20 | 28.8％ | 40 | 37.4％ | 80 | 45.2％ |
| 4B-2 | 20 | 28.2％ | 40 | 38.7％ | 80 | 44.9％ |
Table 3: to the curative effect (tumour inhibiting rate) of intracranial in-situ inoculating mice cerebroma G422 model.
| Injection | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate |
| 1A | 20 | 47.7％ | 40 | 59.5％ | 80 | 68.3％ |
| 1B | 20 | 46.8％ | 40 | 59.3％ | 80 | 68.5％ |
| 2A | 20 | 47.3％ | 40 | 57.7％ | 80 | 64.0％ |
| 2B | 20 | 48.3％ | 40 | 56.2％ | 80 | 63.7％ |
| 3A | 20 | 49.5％ | 40 | 59.7％ | 80 | 67.5％ |
| 3B | 20 | 48.4％ | 40 | 58.2％ | 80 | 66.4％ |
| 4A-1 | 20 | 49.2％ | 40 | 58.4％ | 80 | 67.0％ |
| 4A-2 | 20 | 49.4％ | 40 | 57.6％ | 80 | 67.3％ |
| 4B-1 | 20 | 48.7％ | 40 | 57.3％ | 80 | 66.2％ |
| 4B-2 | 20 | 49.2％ | 40 | 58.4％ | 80 | 67.9％ |
| 5A | 20 | 49.8％ | 40 | 58.6％ | 80 | 68.2％ |
| 5B | 20 | 47.8％ | 40 | 58.2％ | 80 | 65.5％ |
| 6A | 20 | 47.7％ | 40 | 56.8％ | 80 | 63.3％ |
| 6B | 20 | 46.9％ | 40 | 56.9％ | 80 | 63.5％ |
| 7A | 20 | 48.3％ | 40 | 56.4％ | 80 | 66.0％ |
| 7B | 20 | 46.8％ | 40 | 56.3％ | 80 | 63.3％ |
Table 4: to the curative effect (tumour inhibiting rate) of subcutaneous vaccination mice cerebroma G422 model.
| Injection | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate | Dosage (mg/kg) | Tumour inhibiting rate |
| 1A | 20 | 23.1％ | 40 | 29.8％ | 80 | 35.4％ |
| 1B | 20 | 23.0％ | 40 | 29.7％ | 80 | 35.3％ |
| 2A | 20 | 22.8％ | 40 | 27.8％ | 80 | 34.0％ |
| 2B | 20 | 22.8％ | 40 | 28.5％ | 80 | 33.2％ |
| 3A | 20 | 22.9％ | 40 | 29.8％ | 80 | 34.3％ |
| 3B | 20 | 23.0％ | 40 | 28.6％ | 80 | 34.8％ |
| 4A-1 | 20 | 24.3％ | 40 | 28.1％ | 80 | 36.3％ |
| 4A-2 | 20 | 24.4％ | 40 | 27.9％ | 80 | 36.3％ |
| 4B-1 | 20 | 23.7％ | 40 | 27.8％ | 80 | 35.3％ |
| 4B-2 | 20 | 23.3％ | 40 | 28.6％ | 80 | 34.4％ |
| 5A | 20 | 23.4％ | 40 | 28.6％ | 80 | 34.8％ |
| 5B | 20 | 24.1％ | 40 | 28.7％ | 80 | 34.5％ |
| 6A | 20 | 22.4％ | 40 | 27.9％ | 80 | 33.3％ |
| 6B | 20 | 22.7％ | 40 | 27.8％ | 80 | 33.4％ |
| 7A | 20 | 22.4％ | 40 | 27.5％ | 80 | 34.1％ |
| 7B | 20 | 22.3％ | 40 | 27.2％ | 80 | 33.7％ |
In addition, the injection of various dosage forms improves 21%～23% to the NK cells in mice and the matched group specific activity of lotus Lewis lung cancer.
The injection of various dosage forms has improved 1.4～1.55 to the influence of mouse lymphocyte proliferation activity, the stimulation index of lotus Lewis lung cancer.
In a word, from above-mentioned table data as can be seen, various preparations are effective through QGY hepatocarcinoma, MKN-45 gastric cancer, mice cerebroma G422 model pharmacology test.To the Immune Function test, the NK cells in mice of lotus Lewis lung cancer improves 21%～23% with the matched group ratio.Lymphocyte increment activity influence, stimulation index have improved 1.4～1.55.
So injection can be used in and suppresses and/or the treatment tumor.In addition, through overtesting, said preparation can also be used for anticancer to be shifted, and is used for tumor remission pain, is used for prevention or treatment cerebral infarction.
Claims (9)
1. common turmeric extract fat emulsion injection, it contains: the extract with total sesquiterpene alkene class content 〉=70wt% that extracts from the RADIX CURCUMAE plant, soybean phospholipid, soybean oil, glycerol and water for injection, it is characterized in that: this injection is a kind of aqueous dispersion, the mean diameter of decentralized photo≤1 micron, wherein extract accounts for 0.08～0.8wt% of final preparaton total amount, soybean phospholipid accounts for 0.8～2.5wt%, soybean oil accounts for 8～12wt%, glycerol accounts for 1.8～2.8wt%, water for injection adds to 5000ml, and the ultimate density of sesquiterpene active component is 1-10mg/ml in the common turmeric extract fat emulsion injection.
2. common turmeric extract fat emulsion injection according to claim 1, it is characterized in that: described extract accounts for the 0.1wt%～0.5wt% of final preparaton total amount, soybean phospholipid accounts for 1.2wt%～2.0wt%, and soybean oil accounts for 10wt%, and glycerol accounts for 2.25wt%～2.5wt%.
3. common turmeric extract fat emulsion injection according to claim 1 is characterized in that: the ultimate density of sesquiterpene active component is 2～7.5mg/ml in the described common turmeric extract fat emulsion injection.
4. common turmeric extract fat emulsion injection according to claim 2 is characterized in that: the ultimate density of sesquiterpene active component is 2～7.5mg/ml in the described common turmeric extract fat emulsion injection.
5. according to the described common turmeric extract fat emulsion injection of arbitrary claim among the claim 1-4, it is characterized in that: described extract contains 1/50～1/10 the curcumin that is equivalent to the sesquiterpene gross weight.
6. the preparation method of the described common turmeric extract fat emulsion injection of claim 1, it comprises the steps:
(1), the extract that from the RADIX CURCUMAE plant, extracts with total sesquiterpene alkene class content 〉=70wt%;
(2), extract that step (1) is obtained is according in extract and the soybean phospholipid adding soybean oil, heats up into oil phase, and this oil phase is joined in the glycerinated aqueous solution, utilizes Rotary Evaporators film forming or CO
2Critical or supercritical process mix homogeneously, add water for injection, handle through high pressure homogenizing, till the stabilized aqueous dispersion that obtains particle diameter of dispersing phase≤1 micron, thereby make injection, wherein extract accounts for the 0.08wt%～0.8wt% of final preparaton total amount, soybean phospholipid accounts for 0.8wt%～2.5wt%, soybean oil accounts for 8wt%～12wt%, glycerol accounts for 1.8wt%～2.8wt%, water for injection adds to 5000ml, and the ultimate density of sesquiterpene active component is 1-10mg/ml's in the common turmeric extract fat emulsion injection.
7. preparation method according to claim 6 is characterized in that: described extract accounts for the 0.1wt%～0.5wt% of final preparaton total amount, and soybean phospholipid accounts for 1.2wt%～2.0wt%, and soybean oil accounts for 10wt%, and glycerol accounts for 2.25wt%～2.5wt%.
8. according to claim 6 or 7 described preparation methoies, it is characterized in that: described extract contains 1/50～1/10 the curcumin that is equivalent to the sesquiterpene gross weight.
9. the described common turmeric extract fat emulsion injection of arbitrary claim is used to prepare the purposes that suppresses or treat the medicine of cancer among the claim 1-5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021172188A CN100423713C (en) | 2002-04-17 | 2002-04-17 | Curcuma aromatica extract injection, and preparing method and use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021172188A Division CN100423713C (en) | 2002-04-17 | 2002-04-17 | Curcuma aromatica extract injection, and preparing method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101306183A CN101306183A (en) | 2008-11-19 |
| CN101306183B true CN101306183B (en) | 2011-06-29 |
Family
ID=29221083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810126418.1A Expired - Lifetime CN101306184B (en) | 2002-04-17 | 2002-04-17 | Common turmeric extract vein emulsion injection and its production and use |
| CNB021172188A Expired - Lifetime CN100423713C (en) | 2002-04-17 | 2002-04-17 | Curcuma aromatica extract injection, and preparing method and use thereof |
| CN2008101264177A Expired - Lifetime CN101306183B (en) | 2002-04-17 | 2002-04-17 | Common turmeric extract fat emulsion injection and its preparation method and use |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810126418.1A Expired - Lifetime CN101306184B (en) | 2002-04-17 | 2002-04-17 | Common turmeric extract vein emulsion injection and its production and use |
| CNB021172188A Expired - Lifetime CN100423713C (en) | 2002-04-17 | 2002-04-17 | Curcuma aromatica extract injection, and preparing method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN101306184B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486567C (en) * | 2004-08-12 | 2009-05-13 | 山东绿叶天然药物研究开发有限公司 | Curcumin emulsion and its preparation process |
| CN101569606A (en) * | 2009-06-09 | 2009-11-04 | 沈阳药科大学 | Curcumol liposome and preparation method thereof |
| CN109444283A (en) * | 2018-12-12 | 2019-03-08 | 广西中医药大学 | The detection method of curcumin chemical compounds in a kind of osmanthus Radix Curcumae |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076613A (en) * | 1993-02-15 | 1993-09-29 | 大连金港制药有限公司 | Elemene emulsion injection and preparation method thereof |
| CN1200266A (en) * | 1997-04-14 | 1998-12-02 | 中国科技开发院医药科技开发所 | Method for preparing anti-cancer medicine using beta-elemene as main effective ingredient, and components of the medicine |
| CN1221607A (en) * | 1998-11-20 | 1999-07-07 | 大连市医药科学研究所 | Liposoluble medicinal liposome prodn. tech. and elemene liposome injecta |
-
2002
- 2002-04-17 CN CN200810126418.1A patent/CN101306184B/en not_active Expired - Lifetime
- 2002-04-17 CN CNB021172188A patent/CN100423713C/en not_active Expired - Lifetime
- 2002-04-17 CN CN2008101264177A patent/CN101306183B/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076613A (en) * | 1993-02-15 | 1993-09-29 | 大连金港制药有限公司 | Elemene emulsion injection and preparation method thereof |
| CN1200266A (en) * | 1997-04-14 | 1998-12-02 | 中国科技开发院医药科技开发所 | Method for preparing anti-cancer medicine using beta-elemene as main effective ingredient, and components of the medicine |
| CN1221607A (en) * | 1998-11-20 | 1999-07-07 | 大连市医药科学研究所 | Liposoluble medicinal liposome prodn. tech. and elemene liposome injecta |
Non-Patent Citations (1)
| Title |
|---|
| 陈颖等.环孢素纳米脂质体的制备及在小鼠体内的组织分布.《中国新药与临床杂志》.2002,第21卷(第2期),第81-83页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101306184B (en) | 2015-09-23 |
| CN100423713C (en) | 2008-10-08 |
| CN101306184A (en) | 2008-11-19 |
| CN101306183A (en) | 2008-11-19 |
| CN1451376A (en) | 2003-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102671140B (en) | Anticancer traditional Chinese medicine combination oral liquid, preparation method and detection method thereof | |
| CN102416139A (en) | Chinese medicine composition for treating breast diseases | |
| CN101513519A (en) | Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof | |
| CN101306182B (en) | Elemene vein emulsion injection and preparation method thereof | |
| CN101306183B (en) | Common turmeric extract fat emulsion injection and its preparation method and use | |
| CN100434066C (en) | Curcuma longa extract injection, and preparing process and use thereof | |
| CN100471490C (en) | Sesquiterpene ketone injection, preparing method and use thereof | |
| CN102319319A (en) | Solanum lyratum extract, and anticancer medicine comprising solanum lyratum extract | |
| CN102225180A (en) | Traditional Chinese medicine composition having anticancer effect and preparation method thereof | |
| CN100512805C (en) | Sesquiterpene injection, preparing method and use thereof | |
| CN101244105B (en) | Pseudo-ginseng standard extract P1237, its pharmaceutical combination, its preparing method and its uses | |
| CN102362971A (en) | Traditional Chinese medicine for treating coronary disease, preparation method of active chemical ingredients thereof and preparation | |
| CN1970054B (en) | Method for extracting anticancer extract from citronella oil, composition and use thereof | |
| CN101472600A (en) | Medicament composition for regulating blood sugar and blood fat as well as preparation method and application thereof | |
| CN101642492B (en) | Drug for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN1302769C (en) | Curcuma oil extract injection aqueous solution and preparation method and application thereof | |
| CN105232627A (en) | Solidago extract and preparation method and medical application thereof | |
| CN105267283A (en) | Pharmaceutical composition with efficacy of reducing blood fat and preparation method of pharmaceutical composition | |
| CN100473399C (en) | Compound wurenchun capsule fortreating organizing and chronic hepatitis | |
| CN115969903B (en) | Traditional Chinese medicine composition, preparation method thereof and application of traditional Chinese medicine composition in preparation of medicines with fatty liver prevention and treatment effects | |
| CN1269522C (en) | Traditional Chinese medicine for treating cancer and its preparation method | |
| CN102451442A (en) | Extraction process of anti-depression Chinese medicament | |
| CN101406683A (en) | Chinese medicine compound and preparation method thereof | |
| CN116920010A (en) | Preparation method of Yupingfeng compound traditional Chinese medicine preparation | |
| CN100444860C (en) | Compound Chinese medicinal extract mixture and its prepration method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081119 Assignee: Dalian Holley Kingkong Pharmaceutical Co., Ltd. Assignor: Xie Tian Contract record no.: 2013210000024 Denomination of invention: Common turmeric extract fat emulsion injection and its preparation method and use Granted publication date: 20110629 License type: Exclusive License Record date: 20130329 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| ASS | Succession or assignment of patent right |
Owner name: DALIAN HOLLEY KINGKONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XIE TIAN Effective date: 20150310 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310013 HANGZHOU, ZHEJIANG PROVINCE TO: 116100 DALIAN, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150310 Address after: Jinzhou District of Dalian City, Liaoning province 116100 Chengen Street No. 8 Patentee after: Dalian Holley Kingkong Pharmaceutical Co., Ltd. Address before: Is 310013 Hangzhou Road, Zhejiang province No. 36 Luyuan Ginkgo Garden 3-1902 Patentee before: Xie Tian |
|
| CX01 | Expiry of patent term |
Granted publication date: 20110629 |
|
| CX01 | Expiry of patent term |